BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AS703026: Preliminary Phase I data

Preliminary data from an ongoing, open-label, dose-escalation Phase I trial in 68 patients showed that AS703026 produced 2 confirmed partial responses in previously-treated melanoma patients, 1 at a dose of 68 mg/day AS703026...

Read the full 142 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >